Search clinical trials for: Etelcalcetide

Total 21 results

Thomas Nickolas, MD MS

Completed

The Effect of Etelcalcetide on CKD-MBD (Parsabiv-MBD)

Vascular Calcification | Chronic Kidney Disease Mineral and Bone Disorder | Hyperparathyroidism; Secondary, Renal | Renal Osteodystrophy

United States
Prim. Priv. Doz. Dr. Daniel Cejka
Amgen

Completed

A Study to Investigate the Influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients

End Stage Renal Disease

Austria
Amgen

Completed

A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis

Chronic Kidney Disease, Secondary Hyperparathyroidism

Belgium, United States, Germany, Poland, United Kingdom, Lithuania
Amgen

Recruiting

A Study of Etelcalcetide in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

Chronic Kidney Disease | Secondary Hyperparathyroidism

Korea, Republic of, United States, Turkey, India, Singapore, Taiwan, Argentina, Malaysia, Russian Federation, Ukraine
Amgen

Completed

Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis

Hyperparathyroidism, Secondary

United States, Belgium, Italy, United Kingdom, Canada, Germany, Spain, Australia, Austria, Israel, Czechia, Hungary, Netherlands, Poland, France, Russian Federation, Sweden
KAI Pharmaceuticals
Nucleus Network Ltd

Completed

Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Healthy Male Volunteers

Hyperparathyroidism, Secondary

Australia
Amgen

Completed

A Phase 1 Study to Evaluate PK, Safety and Tolerability of AMG 416

Secondary Hyperparathyroidism

China
KAI Pharmaceuticals

Completed

Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism

Hyperparathyroidism, Secondary

United States, Australia
Amgen

Completed

Pharmacokinetics and Excretion of [¹⁴C]Etelcalcetide (AMG 416) in Patients With End Stage Renal Disease (ESRD) Receiving Dialysis

Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis

United States
KAI Pharmaceuticals

Completed

Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism

Secondary Hyperparathyroidism

United States
Allergan

Enrolling by invitation

A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)

Irritable Bowel Syndrome

United States
Amgen

Recruiting

A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis

Secondary Hyperparathyroidism

Spain, Belgium, Germany, Czechia, Poland, France, Greece, Hungary, Italy, United Kingdom, Lithuania, Portugal
Amgen

Completed

Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis

Hyperparathyroidism, Secondary

United States, Belgium, Canada, France, Australia, Israel, Czechia, Hungary, Netherlands, Spain, Poland, Russian Federation, Italy, Sweden, Germany
KAI Pharmaceuticals

Completed

Etelcalcetide to Treat Secondary Hyperparathyroidism in Hemodialysis Patients With Chronic Kidney Disease-Mineral and Bone Disorder

Secondary Hyperparathyroidism
Amgen

Completed

Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis

Hyperparathyroidism, Secondary

United States, Belgium, Italy, United Kingdom, Canada, Germany, Spain, Austria, Czechia, Hungary, France, Israel, Poland, Australia, Russian Federation
Amgen

Completed

Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide

Hyperparathyroidism, Secondary

United States
Hospices Civils de Lyon

Completed

Effect of Active Vitamin D and Etelcalcetide on Human Osteoclasts in Patients With Chronic Kidney Disease (RENOCLASTE)

Chronic Kidney Diseases | Bone Disorder

France
Amgen

Completed

Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis

Hyperparathyroidism, Secondary

United States, Belgium, Italy, Switzerland, Canada, Turkey, Spain, Australia, Austria, Israel, Czechia, Hungary, Poland, France, Russian Federation, Germany, Denmark, Greece, Latvia, Lithuania, Netherlands, New Zealand, Portugal, Sweden
KAI Pharmaceuticals

Terminated

Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism

Secondary Hyperparathyroidism
Amgen

Completed

Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)

Chronic Kidney Disease | Secondary Hyperparathyroidism

Korea, Republic of, Taiwan, Hong Kong, China, India, Malaysia
Amgen

Completed

Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet

Chronic Kidney Disease | Secondary Hyperparathyroidism

United States, Italy, Belgium, Denmark, Switzerland, Canada, Turkey, Spain, Austria, Germany, Hungary, Greece, France, Poland, Russian Federation, Czechia, Latvia, Lithuania, New Zealand, Portugal, Sweden, Estonia

Search clinical trials for: Etelcalcetide

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations